Connect with us

Press Releases

Licensed Counselor and Motivational Speaker, Kelly Houseman, Launches Mental Health Podcast “Kelly’s Reality”

Kelly’s Reality, a mental health podcast hosted by Kelly Houseman MS, LLPC that will interview notable public figures with inspiring stories, this week officially launched for listeners everywhere. Exploring a “taboo topic” of mental health for adults that is all too often ignored in everyday life today, Kelly’s Reality will provide listeners with best life… Read more »

Avatar

Published

on

Industry: Psychology

Kelly’s Reality, a mental health podcast hosted by Kelly Houseman MS, LLPC that will interview notable public figures with inspiring stories, this week officially launched for listeners everywhere.

Detroit, MI (PRUnderground) August 23rd, 2020

Kelly’s Reality, a mental health podcast hosted by Kelly Houseman MS, LLPC that will interview notable public figures with inspiring stories, this week officially launched for listeners everywhere.

Exploring a “taboo topic” of mental health for adults that is all too often ignored in everyday life today, Kelly’s Reality will provide listeners with best life advice, background information on how the speakers got to where they are today, and most importantly, how these individuals maintain strong psychological health.

“The goal with this podcast is to leave listeners feeling encouraged to explore new mindsets and thinking. It’s a much-needed break from reality,” said Houseman. “I want to end the stigma and get comfortable talking about mental health and therapy. It’s something natural that should be accepted and discussed today.”

Some of the first guests to appear on Kelly’s Reality include: Jay Shetty, Gabriela Isler, John Salley, Kristina Kuzmic, and Dr. Judy Ho.

Houseman is a licensed therapist and mental health advocate, public speaker, blogger, podcast host, and wellness expert based out of the Detroit-region. She carries an MS degree in Mental Health Counseling and a BS in Communications.

Houseman is known for helping to reduce the stigma surrounding mental health issues by bringing humor and insight into the discussion. She has been featured on television, radio, and print, including ABC, Bustle, and Fox.

“It is my intention to grow Kelly’s Reality into a community – a safe haven where people can relax and entertain new perspectives,” said Houseman. “Everyone can use a little mental health boost. Spread the word today!”

Houseman can be followed on Instagram at @kellysreality and YouTube at Kelly’s Reality.

For more information, visit: https://kellysreality.com/podcast.

About Kelly’s Reality

Print Friendly, PDF & Email

Source: https://www.prunderground.com/licensed-counselor-and-motivational-speaker-kelly-houseman-launches-mental-health-podcast-kellys-reality-2/00200941/

Continue Reading

Press Releases

ACLU Calls Prop 24 “Fake Privacy,” Warns About its “Pay for Privacy” Provision

SACRAMENTO, Calif., Oct. 24, 2020 /PRNewswire/ — The American Civil Liberties Union (ACLU) of California reiterated its opposition to Proposition 24. The statewide ACLU endorsed No on Prop 24 following board approval of opposition to the ballot measure by each of its three California…

Avatar

Published

on

SACRAMENTO, Calif., Oct. 24, 2020 /PRNewswire/ — The American Civil Liberties Union (ACLU) of California reiterated its opposition to Proposition 24. The statewide ACLU endorsed No on Prop 24 following board approval of opposition to the ballot measure by each of its three California chapters: ACLU of Northern California, ACLU of Southern California and ACLU of San Diego and Imperial Counties.

A post issued by the ACLU of Northern California states that the ballot measure would undermine privacy protections and “increase the burden on people to protect themselves” from big tech companies’ abuse of personal information.

In a blog statement released on October 16, 2020, Jake Snow and Chris Conley of the ACLU of Northern California wrote, “Californians shouldn’t have to pay for privacy, particularly when the Constitution guarantees privacy as an inalienable right.” They state that instead of combatting pay for privacy schemes, Prop 24 “makes it worse with a new exception that allows companies to charge you more if you tell them not to sell your personal information.”

The ACLU of Northern California commentary said, “Prop 24 is also full of loopholes that undermine consumer privacy, including a carveout written by the credit-reporting industry, weakened privacy protections for Californians when they travel, and new ways to keep consumers in the dark about what companies are doing with their personal information. For every step forward, there are two steps back. That approach won’t advance privacy in California.”  The full ACLU of Northern California commentary is available at: https://www.aclunc.org/blog/californians-should-vote-no-prop-24

The ACLU of Southern California wrote that Prop 24 is a “fake privacy law. Instead of increasing protections, it requires people to jump through more hoops and adds anti-privacy loopholes for big business.”  The ACLU of Southern California statement is available at: https://www.aclusocal.org/2020ballotguide

Several other privacy and consumer rights advocates join the ACLU in opposition to Prop 24. The Consumer Federation of California, Consumer Action, Public Citizen, California Alliance for Retired Americans, TURN – The Utility Reform Network, Center For Digital Democracy, Consumer Federation of America, Consumer for Automobile Reliability and Safety, and Media Alliance urge Californians to vote no on Prop 24.

The League of Women Voters of California, Color of Change, the California Nurses Association, labor and civil rights leader Dolores Huerta, and numerous other advocates for consumers, labor, immigrants, communities of color and small business oppose Prop 24, as do 25 newspapers editorials.

Learn more about how Prop 24 undermines consumer privacy rights and harms small business at: prop24no.org

SOURCE Californians for Real Privacy – No on Proposition 24

Source: https://www.prnewswire.com:443/news-releases/aclu-calls-prop-24-fake-privacy-warns-about-its-pay-for-privacy-provision-301159163.html

Continue Reading

Press Releases

ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium

HOUSTON and VANCOUVER, BC, Oct. 24, 2020 /PRNewswire/ – ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA’s clinical candidate,…

Avatar

Published

on

HOUSTON and VANCOUVER, BC, Oct. 24, 2020 /PRNewswire/ – ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA’s clinical candidate, EPI-7386, at the 32nd EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics (“ENA”).

In an oral poster presentation titled, “The pre-clinical characterization of the N-terminal domain androgen receptor inhibitor, EPI-7386, for the treatment of prostate cancer”, was published on Saturday, October 24th.

The studies highlight new information about EPI-7386 including:

    • In an in vitro cellular thermal shift assay (CETSA), EPI-7386 was shown to physically interact with the both the full-length and the splice variant (AR-V7) form of the androgen receptor (“AR”).
    • In an in vitro full-length AR-driven cellular model (LNCaP), RNAseq data was analyzed by pathway enrichment analysis. EPI-7386 demonstrates largely similar modulation of AR-regulated genes compared to enzalutamide, but with additional unique elements.
    • EPI-7386 exhibits superior activity to enzalutamide in the AR-V7-driven cellular models LNCaP95 and 22Rv1 by modulating AR-driven gene expression with or without the addition of an external androgen.

“Previously, we presented in vitro data demonstrating that EPI-7386 binds to the full-length androgen receptor and can inhibit the transcription of AR-regulated genes. These new data demonstrate that EPI-7386 can also physically interact with the splice variant form, AR-V7, of the androgen receptor and inhibit its activity. The importance of this interaction with AR-V7 is seen through the superior transcriptional inhibition of AR-regulated genes by EPI-7386 compared to enzalutamide in the AR-V7-driven cell models LNCaP95 and 22Rv1. Together, these data provide important new insights into mechanistic aspects related to the binding and utility of EPI-7386 against AR-V7 splice-variant driven prostate cancer models. The data further strengthen the rationale for studying EPI-7386 in men with prostate cancer resistant to current anti-androgens.” said Dr. David R. Parkinson, President and Chief Executive Officer.  

About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer in patients whose disease is progressing despite treatment with current therapies. ESSA’s proprietary “aniten” compounds bind to the N-terminal domain of the androgen receptor (“AR”), inhibiting AR driven transcription and the AR signaling pathway in a unique manner which bypasses the drug resistance mechanisms associated with current anti-androgens. The Company is currently conducting a phase 1 study of EPI-7386 in patients with metastatic castration-resistant prostate cancer (“mCRPC”) who are failing current standard-of-care therapies. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.

About Prostate Cancer
Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking androgen action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone generally represents a transition to the lethal variant of the disease, mCRPC, and most patients ultimately succumb to the illness. The treatment of mCRPC patients has evolved rapidly over the past five years. Despite these advances, additional treatment options are needed to improve clinical outcomes in patients, particularly those who fail existing treatments including abiraterone or enzalutamide, or those who have contraindications to receive those drugs. Over time, patients with mCRPC generally experience continued disease progression, worsening pain, leading to substantial morbidity and limited survival rates. In both in vitro and in vivo animal studies, ESSA’s novel approach to blocking the androgen pathway has been shown to be effective in blocking tumor growth when current therapies are no longer effective.

Forward-Looking Statement Disclaimer
This release contains certain information which, as presented, constitutes “forward-looking information” within the meaning of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information involves statements that relate to future events and often addresses expected future business and financial performance, containing words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions and includes, but is not limited to, the results of preclinical data on EPI-7386 including the potential utility of EPI-7386 against AR-V7 splice-variant driven prostate cancer models.

Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause ESSA’s actual results, performance or achievements to be materially different from those expressed or implied thereby. Such statements reflect ESSA’s current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i) the accuracy of ESSA’s financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market and economic conditions.

Forward-looking information is developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA’s Annual Report on Form 20-F dated December 19, 2019 under the heading “Risk Factors”, a copy of which is available on ESSA’s profile on the SEDAR website at www.sedar.com, ESSA’s profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA’s SEDAR profile. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable Canadian and United States securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE ESSA Pharma Inc

Related Links

essapharmaceuticals.com

Source: https://www.prnewswire.com:443/news-releases/essa-pharma-presents-therapeutic-potential-of-epi-7386-at-32nd-eortc-nci-aacr-symposium-301159162.html

Continue Reading

Press Releases

Lianluo Smart Limited and Newegg Inc. Announce Entering into Merger Agreement

BEIJING, Oct. 24, 2020 /PRNewswire/ — Lianluo Smart Limited (“LLIT” or the “Company”) (NASDAQ: LLIT), and privately-held Newegg Inc. (“Newegg”) today jointly announced that they have entered into an Agreement and Plan of Merger (the “Merger Agreement”), whereby the stockholders of Newegg…

Avatar

Published

on

BEIJING, Oct. 24, 2020 /PRNewswire/ — Lianluo Smart Limited (“LLIT” or the “Company”) (NASDAQ: LLIT), and privately-held Newegg Inc. (“Newegg”) today jointly announced that they have entered into an Agreement and Plan of Merger (the “Merger Agreement”), whereby the stockholders of Newegg will become the majority owners of LLIT, as a result of the merger of Lightning Delaware Sub, Inc. (the “Merger Sub”), LLIT’s wholly owned subsidiary, with and into Newegg.  In addition, LLIT will sell its equity holdings in Lianluo Connection Medical Wearable Device Technology (Beijing) Co., Ltd. (“Lianluo Connection”) to Beijing Fenjin Times Technology Development Co., Ltd (“Fenjin Times“) pursuant to an equity transfer agreement (“Disposition Agreement”). The disposition will become effective immediately following completion of the Merger. 

Concurrent with the closing of the merger and disposition described above (collectively, the “Restructure”), the Company will conduct a public offering of its common shares with expected gross proceeds of approximately $30 million (the “Financing”). The consummation of the Restructure and the Financing are contingent on the closing of each other transaction and certain customary approvals and conditions. LLIT will seek its shareholders’ approval of the Restructure as well as an amendment to its memorandum and articles of association to eliminate its dual class share structure, to effectuate a reverse share split if needed to meet Nasdaq’s initial listing requirements, to increase the number of its authorized shares and to effectuate a name change.

LLIT’s Class A common shares are currently traded on Nasdaq under the symbol “LLIT”. In connection with the closing of the Restructure and the Financing, LLIT intends to change its name to “Newegg Commerce, Inc.” and remain Nasdaq-listed under a new ticker symbol.  Upon completion of the merger, the board of directors and officers of LLIT will be replaced by the board of directors and officers of Newegg.

Newegg is a leading e-commerce company in North America offering direct sales and an online marketplace platform for consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services and marketing services globally.

“Over the course of nearly two decades, Newegg built a highly reputable and widely recognized name in the tech-focused ecommerce market. As we prepare to become a publicly traded company, we are well positioned to build on this foundation to take Newegg to the next level,” said Anthony Chow, Global CEO of Newegg. “Combining our deep market expertise in ecommerce and leadership in technology, we are structured and prepared to capitalize on new strategic initiatives and partnerships.”

Key Terms of the Transactions

Merger

Under the terms of the Merger Agreement, the Merger Sub will merge with and into Newegg, with Newegg surviving the merger as a wholly-owned subsidiary of LLIT. Upon completion of the merger, the Class B common shares of LLIT will be eliminated and LLIT will only have one class of securities, which will be referred to as common shares. The holder of all outstanding Class B common shares and warrants has elected to convert those shares into the same number of common shares and amend those warrants to be exercisable for the same number of common shares at the same aggregate exercise price, effective immediately prior to completion of the merger. Pursuant to the Merger Agreement, LLIT will issue approximately 363,325,542 common shares to the Newegg stockholders as the merger consideration. 

It is anticipated that immediately upon completion of the merger, Newegg’s current stockholders will have an ownership interest of approximately 99.02%, and LLIT’s existing shareholders will own approximately 0.98%, of the post-merger company. The above ownership percentages do not take into account the Company’s proposed Financing of common shares that is contemplated to take place concurrently with the Restructure.

Disposition

Simultaneously with the execution of the Merger Agreement, the Company entered into the Disposition Agreement with Fenjin Times. Pursuant to the Disposition Agreement, the Company will sell all of the equity interest in its sole operating subsidiary, Lianluo Connection to Fenjin Times for cash consideration of $0. In addition, as the new owner of Lianluo Connection, Fenjin Times is obligated to make a contribution of RMB87.784 million to Lianluo Connection’s registered capital by September 23, 2023 in accordance with the articles of association of Lianluo Connection.  The Company also agreed to convert the debt owed by Lianluo Connection to the Company in the aggregate amount of $11,255,188 into additional paid-in capital of Lianluo Connection.  Upon completion of this disposition, Lianluo Connection will be 100% owned by Fenjin Times.

Approvals, Opinions and Conditions

The Company will seek its shareholders’ approval of the Restructure as well as other related proposals including the elimination of its dual class structure, an increase of the authorized shares, share combination, name change, and amendment of its memorandum and articles of association. 

The proposed Restructure has been unanimously approved by the board of directors of LLIT.  The Merger Agreement was also approved by all of the board members of Newegg and adopted by a majority of holders of each class of outstanding capital stock of Newegg. Since Hangzhou Lianluo Interactive Technology Co., Ltd. (“Hangzhou Lianluo”) is the direct or indirect controlling shareholder of both LLIT and Newegg, the proposed Restructure has been unanimously approved by the special committee of board of directors of LLIT and the proposed Merger Agreement has been unanimously approved by the special committee of the board of directors of Newegg.

The Benchmark Company, LLC (“Benchmark”) is acting as financial advisor to the Company. Benchmark provided a fairness opinion indicating that the merger consideration to be paid by the Company is fair to the shareholders of LLIT from a financial point of view and another fairness opinion indicating that the consideration to be received by the Company in the disposition is fair to the shareholders of LLIT from a financial point of view.

Completion of the Restructure and the Financing is subject to a number of conditions, including, without limitation, approval by LLIT’s shareholders, satisfaction of NASDAQ initial listing requirements, certain third party consents, a registration statement on Form F-4 for the LLIT shares being issued as merger consideration being declared effective by the Securities and Exchange Commission (the “SEC”) and the satisfaction or waiver of other customary closing conditions.  Once the Form F-4 has been declared effective by the SEC, the Company intends to set a date for a special meeting for its shareholders to approve the proposals associated with the Restructure as well as other related proposals described above, and deliver the final notice of shareholders meeting to its shareholders.

About Lianluo Smart Limited

Lianluo Smart Limited (Nasdaq: LLIT) is a professional smart service and products provider, which designs, develops and markets its own branded medical products and medical components in China.

About Newegg Inc.

Newegg, headquartered in the City of Industry, California, is a leading e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally. For more information, please visit https://www.newegg.com/

Advisors

Bevilacqua PLLC is acting as legal counsel to LLIT while Kaufman & Canoles, P.C. is acting as legal counsel to the special committee of LLIT.  Hunter Taubman Fischer & Li LLC is acting as legal counsel to Newegg while Gibson, Dunn & Crutcher LLP served as legal counsel to the special committee of Newegg.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of U.S. federal securities laws. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, LLIT’s and Newegg’ expectations with respect to future performance, growth and anticipated acquisitions; the anticipated financial impact of the Restructure; ability to recognize the anticipated benefits of the merger; costs related to the proposed Restructure; the satisfaction of the closing conditions to the Restructure; the timing of the completion of the Restructure; demand for consumer electrics; impact of the COVID-19 pandemic; global economic conditions; geopolitical events and regulatory changes; loss of key personnel; difficulty managing planned growth properly; access to additional financing; changes in tax laws; changing interpretations of generally accepted accounting principles; inquiries and investigations and related litigation; continued compliance with government regulations; and other risks and uncertainties indicated from time to time in filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning these and other risk factors is contained in LLIT’s most recent filings with the SEC and will be contained in the Form F-4 and other filings to be filed as result of the transactions described above. All subsequent written and oral forward-looking statements concerning LLIT, Merger Sub or Newegg or the transactions described herein or other matters and attributable to LLIT, Merger Sub or Newegg, or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither LLIT, Merger Sub nor Newegg undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based.

Participants in Solicitation

Newegg, LLIT and their respective directors, executive officers and other members of their management and employees may be deemed to be participants in the solicitation of proxies of the Company’s shareholders in connection with the potential transactions described herein under the rules of the SEC. Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of Newegg’s and LLIT’s officers and directors in the registration statement on Form F-4 to be filed with the SEC and will also be contained in the proxy statement/prospectus relating to the proposed transactions when it is filed with the SEC.  These documents may be obtained free of charge from the sources indicated below.

Non-Solicitation

This press release is not a notice of shareholders meeting or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transactions and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of the Company or Newegg Inc., nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Additional Information about the Transactions and Where to Find It

In connection with the proposed Restructure, the Company will file a registration statement on Form F-4 with the SEC and will mail notices of shareholders meeting and other relevant documents to its shareholders. Investors and security holders of the Company are advised to read, when available, the From F-4, and amendments thereto, the notice to shareholders, and amendments thereto, in connection with the Company’s solicitation of proxies for its shareholder’ meeting to be held to approve the transactions described herein because the notice to shareholders will contain important information about the transactions and the parties to the transactions. The notices to shareholders will be mailed to the Company’s shareholders as of a record date to be established for voting on the transactions. Shareholders will also be able to obtain copies of the notice, without charge, once available, at the SEC’s website at www.sec.gov or by directing a request to: Room 611, 6th Floor, BeiKong Technology Building, No. 10 Baifuquan Road, Changping District, Beijing 102200, People’s Republic of China.

A registration statement relating to these securities will be filed with the SEC but has not yet become effective.  These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.  This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  A copy of LLIT’s registration statement on Form F-4, once available, can be viewed on the SEC’s website.

SOURCE Lianluo Smart Limited

Related Links

http://www.lianluosmart.com

Source: https://www.prnewswire.com:443/news-releases/lianluo-smart-limited-and-newegg-inc-announce-entering-into-merger-agreement-301159161.html

Continue Reading
Saas30 mins ago

Saas30 mins ago

Saas30 mins ago

Saas30 mins ago

Saas30 mins ago

Saas30 mins ago

Saas30 mins ago

Saas30 mins ago

Saas30 mins ago

Saas30 mins ago

Press Releases3 hours ago

ACLU Calls Prop 24 “Fake Privacy,” Warns About its “Pay for Privacy” Provision

Press Releases3 hours ago

ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium

Press Releases4 hours ago

Lianluo Smart Limited and Newegg Inc. Announce Entering into Merger Agreement

Saas4 hours ago

Saas4 hours ago

Saas4 hours ago

Saas4 hours ago

Saas4 hours ago

Saas4 hours ago

Saas4 hours ago

Saas4 hours ago

Saas4 hours ago

Saas4 hours ago

Press Releases6 hours ago

Yes on Prop 24 Campaign Announces Endorsement from Data Privacy Advocate and Cambridge Analytica Whistleblower, Brittany Kaiser

Press Releases6 hours ago

Army’s Black Knights Accepts Invitation to Radiance Technologies 2020 Independence Bowl

Press Releases6 hours ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP is Investigating the Following Companies; Investors are Encouraged to Contact the Firm – CEIX, GLIBA

Press Releases6 hours ago

BAK FINAL DEADLINE ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds Braskem S.A. Investors of Important October 26 Deadline in Securities Class Action – BAK

Press Releases7 hours ago

cCARE is on a Myth-Busting Mission to Boost Breast Cancer Awareness

Press Releases7 hours ago

cCARE is on a Myth-Busting Mission to Boost Breast Cancer Awareness

Press Releases7 hours ago

It’s Time To Celebrate #SecureHalloweenWithPureVPN

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Saas7 hours ago

Trending